Summit Partners Public Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Summit Partners Public Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-20,722	Closed	-$6.02M	–	118
2020 Q2	$6.02M	Sell	20,722 -104,236	-83%	-$28.3M	0.36%	70
2020 Q1	$29.7M	Buy	+124,958	New	+$28.7M	2.45%	13
2018 Q1	–	Sell	-70,090	Closed	-$10.5M	–	112
2017 Q4	$10.5M	Buy	70,090 +20,090	+40%	+$2.97M	1.37%	26
2017 Q3	$7.6M	Buy	+50,000	New	+$7.53M	1.03%	38

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Summit Partners Public Asset Management's VRTX Position: Q3 2020 in Review

Summit Partners Public Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2020, closing a stake of 20,722 shares — an estimated $6.02M sold.

Summit Partners Public Asset Management first reported a position in VRTX in Q3 2017 and held it in 4 quarters. The position peaked at $29.7M in Q1 2020. 951 funds tracked by Wall St. Rank hold VRTX as of Q3 2020.

Summit Partners Public Asset Management reported no remaining Vertex Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Summit Partners Public Asset Management sold 20,722 Vertex Pharmaceuticals shares in Q3 2020, an estimated $6.02M.
Summit Partners Public Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2017 and held it in 4 quarters.
Summit Partners Public Asset Management's Vertex Pharmaceuticals position peaked at $29.7M in Q1 2020.
951 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2020.

Based on Summit Partners Public Asset Management's 13F filing for Q3 2020, filed 16 Nov 2020.